Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Lifesaving Ovarian Cancer Chemo Treatment Underutilized, Study Finds

By Drug Discovery Trends Editor | August 5, 2015

Diagram showing stage 3A to 3C ovarian cancer. (Credit: Cancer Research UK / Wikimedia Commons)Women with advanced ovarian cancer who receive intraperitoneal and intravenous (IP/IV) chemotherapy — treatment delivered directly into the abdomen, along with the usual intravenous method — have significantly better survival rates than those who receive IV chemotherapy alone.

The evidence of this is so convincing that in 2006, when a major study showed that the IP method could add 16 months or more to women’s lives, the National Cancer Institute issued a rare recommendation that signified the urgency of changing medical practice to reflect the research.

Yet, today, nearly a decade later, just 41 percent of eligible women are receiving IP chemotherapy, according to a study published Monday in the Journal of Clinical Oncology.

The study looked at IP treatment use at six cancer hospitals, all members of the National Comprehensive Cancer Network, from 2003 to 2012, and at patient survival rates. Alexi Wright, M.D., of Dana-Farber Cancer Institute in Boston, and colleagues, analyzed the records of 823 women with Stage 3, optimally cytoreduced ovarian cancer.

The researchers found the 3-year overall survival (OS) was 81 percent among women who received a combination of IP and intravenous (IV) chemotherapy versus 71 percent for patients who received only intravenous chemotherapy. IP/IV therapy use increased briefly after 2006, but overall use among eligible women was 43 percent from 2006 to 2012, they wrote in the Journal of Clinical Oncology. Rates varied drastically from one hospital to the next, with 4 percent to 67 percent of patients receiving IP treatment — and at smaller, less prestigious hospitals, the rates are even worse, say the researchers.

Wright told The New York Times, “We suspected that even at the best centers there would be low integration of IP chemotherapy, but we were surprised to see how low it was across academic centers, and also to see how much variation there was between centers.”

Reasons for why IP/IV chemotherapy is so underused include toxicity; inconvenience of an inpatient regimen; and a lack of standard guidelines for how to deliver the treatment and train others, which takes time and money.

This year, 21,290 new cases of ovarian cancer are expected in the U.S., and 14,180 deaths, according to the American Cancer Society.

Further recommended reading: Lifesaving Chemo Tx for Ovarian Cancer Often Ignored, MedPage Today


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE